A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M, Both Alone and in Combination, in Healthy UK Adults
Condition: Malaria, Falciparum Intervention: Biological: Matrix M with R78C and/or RH5.1 Sponsor: University of Oxford Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 23, 2022 Category: Research Source Type: clinical trials
